Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

Isotechnika's ISAtx-247 to be developed for third indication: psoriasis

Jan. 26, 2001

Chemokine receptor antagonists designed at the former SmithKline Beecham

Jan. 24, 2001

Cellegy accelerates U.S. filing for Anogesic

Jan. 24, 2001

BioMarin exercises option to product candidate for burns and wounds

Jan. 24, 2001

Phase II trial of P-45 falls short of primary objective

Jan. 23, 2001

Modex completes patient enrollment in EpiDex phase II trial

Jan. 22, 2001

Wyeth-Ayerst seeks FDA approval of new indication of Alesse

Jan. 22, 2001

Meditech licenses Solaraze from SkyePharma

Jan. 22, 2001

Novogen receives grant for development of antiinflammatory drug

Jan. 19, 2001

Development of Fibrostat accelerated in Canada

Jan. 18, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 4, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...